tradingkey.logo

Avalo Therapeutics Inc <AVTX.OQ> expected to post a loss of $1.39 a share - Earnings Preview

ReutersMay 9, 2025 4:12 PM
  • Avalo Therapeutics Inc AVTX.OQ AVTX.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Avalo Therapeutics Inc is for a loss of $1.39 per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 72.4% in the last three months. ​

  • Wall Street's median 12-month price target for Avalo Therapeutics Inc is $30.00​, above​ its last closing price of $4.35. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

0.25

-0.39

-7.95

Missed

-1,929.8

Sep. 30 2024

-1.10

-1.19

-1.25

Missed

-5

Jun. 30 2024

-6.70

-6.70

-14.07

Missed

-110​

Mar. 31 2024

-1.18

-1.18

-1.41 hundred

Missed

-11,849.2

​​Dec. 31 2023

-4.80

-1.16 hundred

Missed

-2,321.1

Sep. 30 2023

-2.64 hundred

-26.40

Beat

90​

Jun. 30 2023

-1.80 hundred

-1.92 hundred

-1.42 hundred

Beat

26.3

Mar. 31 2023

-2.33 hundred

-2.33 hundred

-2.04 hundred

Beat

12.4

This summary was machine generated May 9 at 16:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI